endostar + cisplatin + capecitabine

This drug regimen is a **combination therapy** consisting of **endostar** (recombinant human endostatin), **cisplatin**, and **capecitabine**. Endostar is an anti-angiogenic biologic that inhibits tumor blood vessel formation primarily by blocking multiple angiogenic pathways. Cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and subsequent apoptosis in rapidly dividing cancer cells. Capecitabine is an oral prodrug that is converted to 5-fluorouracil in the body, interfering with DNA synthesis by inhibiting thymidylate synthase. This combination is under investigation primarily for use in **solid tumors**, including gastric and non-small cell lung cancer, where the addition of anti-angiogenic therapy (endostar) to standard chemotherapy (cisplatin + capecitabine) is hypothesized to improve clinical outcomes[7][6][8].

Other names

recombinant human endostatin + cisplatin + capecitabine